BeOne Medicines Ltd. — Director's Dealing 2025

Sep 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeOne Medicines Ltd. (ONC)
CIK: 0001651308
Period of Report: 2025-09-16

Reporting Person: OYLER JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-16	American Depositary Shares	S	4066	$324.1176	Disposed	23737	Direct
2025-09-16	American Depositary Shares	S	6883	$325.062	Disposed	16854	Direct
2025-09-16	American Depositary Shares	S	12446	$326.1362	Disposed	4408	Direct
2025-09-16	American Depositary Shares	S	4008	$326.9029	Disposed	400	Direct
2025-09-16	American Depositary Shares	S	400	$327.78	Disposed	0	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	7450894	Direct
Ordinary Shares	481533	Indirect
Ordinary Shares	7722480	Indirect
Ordinary Shares	28204115	Indirect
Ordinary Shares	9545000	Indirect
Ordinary Shares	102188	Indirect

Footnotes

F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.

F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.

F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

F6: Each American Depositary Share represents 13 Ordinary Shares

F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2025.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.61 to $324.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.61 to $325.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.62 to $326.61, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.62 to $327.20, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.